<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Golivertx</title>
	<atom:link href="https://golivertx.com/feed/?lang=en" rel="self" type="application/rss+xml" />
	<link>https://golivertx.com/?lang=en</link>
	<description></description>
	<lastBuildDate>Fri, 19 Mar 2021 20:59:57 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=5.8.1</generator>
	<item>
		<title>GoLiver Therapeutics is the winner of the French Government‘s</title>
		<link>https://golivertx.com/goliver-therapeutics-is-the-winner-of-the-french-governments/?lang=en</link>
		
		<dc:creator><![CDATA[Dovel]]></dc:creator>
		<pubDate>Fri, 19 Mar 2021 20:40:33 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://golivertx.com/?p=5212</guid>

					<description><![CDATA[<p>GoLiver Therapeutics is the winner of the French Government‘s «Recovery plan for industry &#8211; strategic sectors» call for the implementation of its industrial manufacturing platform project aimed at developing a biomedicine from pluripotent stem cells The aim of this project is to manufacture, in France, a cell therapy product from pluripotent stem cells for the [&#8230;]</p>
The post <a href="https://golivertx.com/goliver-therapeutics-is-the-winner-of-the-french-governments/?lang=en">GoLiver Therapeutics is the winner of the French Government‘s</a> first appeared on <a href="https://golivertx.com/?lang=en">Golivertx</a>.]]></description>
										<content:encoded><![CDATA[<p>GoLiver Therapeutics is the winner of the French Government‘s<br />
«Recovery plan for industry &#8211; strategic sectors» call for the<br />
implementation of its industrial manufacturing platform project<br />
aimed at developing a biomedicine from pluripotent stem cells</p>
<p>The aim of this project is to manufacture, in France, a cell therapy product from<br />
pluripotent stem cells for the treatment of severe liver failure, which currently<br />
has no therapeutic solution other than liver transplantation.<br />
Nantes, France, March 18th 2021 &#8211; GoLiver Therapeutics, a start-up focused on the development of<br />
Advanced Therapy Medical Products, is the winner of the «Recovery plan for industry &#8211; strategic<br />
sectors» call launched by the French Government to support investment and to boost the<br />
competitiveness of French industry.</p>
<p><strong>Industrial and Health Sovereignty</strong><br />
GoLiver Therapeutics, which has developed a biomedicine consisting of an injectable solution of<br />
allogeneic and frozen liver cells, manufactured from pluripotent stem cells, aims to market a cell<br />
therapy product for regenerative medicine at an affordable price and very low production cost.<br />
This €2 million investment, 50% of which is supported by France Relance, makes it possible to partly<br />
finance this crucial step in part, and also welcomes the deployment in France of bioproduction<br />
capacities, which are essential for securing the supply of therapeutic products.</p>
<p>The cell therapy developed by the start-up offers regenerative biomedicine to treat:<br />
&#8211; Severe liver failure with no therapeutic solution other than liver transplantation, the only curative<br />
treatment for end-stage liver diseases;<br />
&#8211; Chronic liver diseases such as non-alcoholic fatty liver disease (NASH).</p>
<p>By allowing patients to live without a liver transplant and with their own regenerated liver, GoLiver<br />
Therapeutic solution will relieve the healthcare system of need for transplants and also allow the<br />
reallocation of transplants to others. Finally, the start-up expects a drastic reduction in the cost per<br />
patient.</p>
<p>This grant comes at a crucial time in the start-up&#8217;s development: production of its biomedicine at an<br />
industrial large-scale to produce clinical batches. This will bring the company closer to a phase I/IIa<br />
clinical trial, for which a partnership agreement with the Paul Brousse Hospital, the 1st liver transplant<br />
center in France, has already been signed.<br />
&#8220;At our current stage of development, finding private funding is not easy because our technology is<br />
truly revolutionary but recent in the pharmaceutical industry. In general, investors prefer to support<br />
biotechs at a more advanced stage and/or with production technologies already proven in industry.</p>
<p>Receiving a significant public fund is a real boost for our development in France and we thank the<br />
French Government for supporting our strategic sector and for having selected our project. Cell<br />
therapy today is a bit like mRNA 10 years ago: Great potential, but a new pharmaceutical industry has<br />
to be built, and this did not make investors dream, whereas today it has made it possible to developthe first vaccines against COVID-19 in record time. We believe that cell therapy, and pluripotent stem<br />
cells in particular, will revolutionize patient care. While GoLiver Therapeutics is primarily focused on<br />
liver disease, our cell therapy may offer solutions for the treatment of other organs.</p>
<p>We believe that France has all the assets to become a leader in the cell therapy industry. We want to contribute to this<br />
at our humble level, because it is in France that we want to write the future of GoLiver Therapeutics<br />
and we hope to attract visionary and audacious investors like us.&#8221; said Tuan Huy Nguyen, President of GoLiver Therapeutics.</p>
<p>&#8220;Liver transplantation is used in cases of terminal liver failure. The patient must then take lifelong<br />
immunosuppressive treatment to modulate the immune defenses and thus reduce graft rejection. This<br />
treatment has certain side effects. What is the alternative to transplantation? Regenerative medicine<br />
for severe liver failure holds promise for avoiding transplantation. Goliver Therapeutics proposes a<br />
solution based on the capacity of one’s own liver cells to regenerate, it is a treatment of the future.&#8221;<br />
says André Le Tutour, Vice-President of TransHepate, the National Federation of Liver Patients and<br />
Transplants and President-Founder of the Regional Association TransHepate Bretagne Ouest at the<br />
University Hospital of Rennes.</p>
<p><strong>About GoLiver Therapeutics &#8211; https://golivertx.com/</strong></p>
<p>GoLiver Therapeutics is a spin-off created in 2017 from Inserm and the University of Nantes (CRTI<br />
UMR1064) focused on developing Advanced Therapy Medicinal Products (ATMPs) to meet a major<br />
medical need in liver transplantation. GoLiver Therapeutics aims to become a world leader in the<br />
regenerative medicine field by tackling liver regeneration, by conducting the first clinical studies and<br />
bringing the first innovative cell-based drug for treating liver diseases without the need for transplant<br />
by using the breakthrough technology of pluripotent stem cells.</p>
<p>Receiving the Seal of Excellence of the European Union in 2020, highlighted by Challenges magazine<br />
as one of the “100 start-ups to invest in” for 2019, GoLiver Therapeutics has been awarded the France<br />
French Transfer Invest 2019, the i-LAB 2016 national Grand Prize for health biotechs and i-LAB 2015<br />
in the emerging start-ups category. Its R&amp;D is supported by BPI France and European Union (ERDF)<br />
funding of €400,000 to develop the first stages of bioproduction process industrialization (2018-2020).</p>
<p><strong>Contact presse</strong><br />
Florence Portejoie I Mob : + 33 6 07 76 82 83 I fportejoie@fp2com.fr</p>
<p>&nbsp;</p>
<p>PDF Link : <a href="https://golivertx.com/wp-content/uploads/2021/03/GoLiver_CP_Subvention_France_Relance_20210318-EN.pdf" target="_blank" rel="noopener">GoLiver_CP_Subvention_France_Relance_20210318 EN</a></p>The post <a href="https://golivertx.com/goliver-therapeutics-is-the-winner-of-the-french-governments/?lang=en">GoLiver Therapeutics is the winner of the French Government‘s</a> first appeared on <a href="https://golivertx.com/?lang=en">Golivertx</a>.]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>News about GoliverTX</title>
		<link>https://golivertx.com/news-about-golivertx/?lang=en</link>
		
		<dc:creator><![CDATA[Dovel]]></dc:creator>
		<pubDate>Sun, 11 Oct 2020 19:34:25 +0000</pubDate>
				<category><![CDATA[Uncategorized]]></category>
		<guid isPermaLink="false">https://golivertx.com/?p=5170</guid>

					<description><![CDATA[<p>03/2021: GOLIVER THERAPEUTICS IS THE WINNER OF THE FRENCH GOVERNMENT’S « RECOVERY PLAN FOR INDUSTRY &#8211; STRATEGIC SECTORS » CALL FOR THE IMPLEMENTATION OF  ITS INDUSTRIAL MANUFACTURING PLATFORM PROJECT AIMED AT  DEVELOPING BIOMEDICINE FROM PLURIPOTENT STEM CELLS ➞ Press communication : GoLiver_CP_Subvention_France_Relance_20210318 EN.pdf ➞ https://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html ➞ https://www.lesechos.fr/pme-regions/innovateurs/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316 ➞ https://nantes.maville.com/actu/actudet_&#8211;medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm ➞ https://biotechinfo.fr/article/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance/ &#160; 11/2020: GoLiver Therapeutics is [&#8230;]</p>
The post <a href="https://golivertx.com/news-about-golivertx/?lang=en">News about GoliverTX</a> first appeared on <a href="https://golivertx.com/?lang=en">Golivertx</a>.]]></description>
										<content:encoded><![CDATA[<p>03/2021: GOLIVER THERAPEUTICS IS THE WINNER OF THE FRENCH GOVERNMENT’S « RECOVERY PLAN FOR INDUSTRY &#8211; STRATEGIC SECTORS » CALL FOR THE IMPLEMENTATION OF  ITS INDUSTRIAL MANUFACTURING PLATFORM PROJECT AIMED AT  DEVELOPING BIOMEDICINE FROM PLURIPOTENT STEM CELLS</p>
<p>➞ <a href="https://golivertx.com/wp-content/uploads/2021/03/GoLiver_CP_Subvention_France_Relance_20210318-EN.pdf" target="_blank" rel="noopener">Press communication : GoLiver_CP_Subvention_France_Relance_20210318 EN.pdf</a></p>
<p><u>➞ <a href="https://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html">https://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/therapie-cellulaire-goliver-therapeutics-sur-les-traces-de-l-arn-messager-880289.html</a></u></p>
<p>➞ <a href="https://www.lesechos.fr/pme-regions/innovateurs/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316">https://www.lesechos.fr/pme-regions/innovateurs/goliver-parie-sur-les-cellules-souches-pour-reparer-le-foie-1299316</a></p>
<p>➞ <a href="https://nantes.maville.com/actu/actudet_--medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm">https://nantes.maville.com/actu/actudet_&#8211;medecine-regenerative-un-nouveau-pas-de-geant-pour-la-start-up-nantaise-goliver-_fil-4544852_actu.Htm</a></p>
<p>➞<a href="https://biotechinfo.fr/article/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance/"> https://biotechinfo.fr/article/goliver-therapeutics-obtient-un-avis-scientifique-positif-de-lagence-europeenne-du-medicament-ema-sur-sa-strategie-de-developpement-clinique-et-de-bioproduction-dans-linsuffisance/</a></p>
<p>&nbsp;</p>
<p>11/2020: GoLiver Therapeutics is awarded with <b>Seal of Excellence Certificate by the European Commission </b>in Horizon H2020-EIC accelerator. After only 3 years of creation, it shows the significance of our project (Excellence, Impact, and Implementation criteria) at the EU level and provides a new guarantee of the quality and potential of our company with its current and future investors, public and private funders, and other stakeholders. Thanks very much to all the liver transplant centers, Pharma companies, Public institutions, and Patient associations that give us a letter of interest, and congrats to the beautiful team!</p>
<p>➞ <a href="https://golivertx.com/wp-content/uploads/2020/10/Seal-of-Excellence-Certificate-by-the-European-Commission-.jpg">https://golivertx.com/wp-content/uploads/2020/10/Seal-of-Excellence-Certificate-by-the-European-Commission-.jpg</a></p>
<p>&nbsp;</p>
<p>06/2020: GoLiver Therapeutics Receives a Positive Scientific Advice from the European Medicine Agency (EMA) on its Clinical Development and Biomanufacturing Strategy for Acute Liver Failure<br />
➞ <a href="https://www.businesswire.com/news/home/20200629005030/en/GoLiver-Therapeutics-Receives-a-Positive-Scientific-Advice-from-the-European-Medicines-Agency-EMA-on-its-Clinical-Development-and-Biomanufacturing-Strategy-for-Acute-Liver-Failure">https://www.businesswire.com/news/home/20200629005030/en/GoLiver-Therapeutics-Receives-a-Positive-Scientific-Advice-from-the-European-Medicines-Agency-EMA-on-its-Clinical-Development-and-Biomanufacturing-Strategy-for-Acute-Liver-Failure</a><br />
➞ GoLiver Therapeutics Receives 急性肝不全に対する臨床開発およびバイオ製造戦略につき欧州医薬品庁（EMA）より肯定的な科学的勧告を受領 (<a href="http://www.qlifepro.com/press/20200630-10-56654/goliver-therapeutics/">http://www.qlifepro.com/press/20200630-10-56654/goliver-therapeutics/</a>)</p>
<p>&nbsp;</p>
<p>12/2019: GoLiver Therapeutics and AP-HP signed a partnership agreement for preparing a phase 1-2a clinical trial for the treatment of sever fulminant liver diseases<br />
➞<a href="https://www.atlanpole.fr/wp-content/uploads/2019/12/CP_GoLiver_20191205_VDEF.pdf">https://www.atlanpole.fr/wp-content/uploads/2019/12/CP_GoLiver_20191205_VDEF.pdf</a><br />
➞<a href="https://www.thepharmaletter.com/article/goliver-seeks-regenerative-alternative-to-liver-transplantation">https://www.thepharmaletter.com/article/goliver-seeks-regenerative-alternative-to-liver-transplantation</a></p>
<p>&nbsp;</p>
<p>12/2019: Le Monde News. Dans les biotechnologies et la santé, le « jeu à la nantaise » fait éclore des pépites.<br />
➞ <a href="https://www.lemonde.fr/campus/article/2019/12/14/dans-les-biotechnologies-et-la-sante-le-jeu-a-la-nantaise-fait-eclore-des-pepites_6022843_4401467.html">https://www.lemonde.fr/campus/article/2019/12/14/dans-les-biotechnologies-et-la-sante-le-jeu-a-la-nantaise-fait-eclore-des-pepites_6022843_4401467.html</a></p>
<p>&nbsp;</p>
<p>09/2019: « French Tech Seed » winner (Bpifrance DeepTech)<br />
➞<a href="https://www.atlanpole.fr/actualites/le-consortium-french-tech-seed-pays-de-la-loire-labellise/">https://www.atlanpole.fr/actualites/le-consortium-french-tech-seed-pays-de-la-loire-labellise/</a></p>
<p>&nbsp;</p>
<p>07/2019: Published paper. Fourrier A et al. Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human induced pluripotent stem cells-derived hepatic stem cells. Xenotransplantation. 2020 Jan;27(1):e12544.<br />
➞<a href="https://pubmed.ncbi.nlm.nih.gov/31342573/">https://pubmed.ncbi.nlm.nih.gov/31342573/</a></p>
<p>&nbsp;</p>
<p>03/2019: GoLiver Therapeutics identified as one of the 100 start-ups where to invest by the Challenges Magazine<br />
➞ <a href="https://www.challenges.fr/classements/start-up/2019/">https://www.challenges.fr/classements/start-up/2019/</a><br />
➞ <a href="https://www.challenges.fr/start-up/goliver-reparer-le-foie-sans-greffe_648605">https://www.challenges.fr/start-up/goliver-reparer-le-foie-sans-greffe_648605</a></p>
<p>&nbsp;</p>
<p>03/2019: GoLiver Therapeutics at BIO-Europe Spring. TH NGUYEN contributed to a roundtable session entitled “What’s NEXT in NASH?<br />
➞<a href="https://www.labiotech.eu/in-depth/nash-treatment/">https://www.labiotech.eu/in-depth/nash-treatment/</a></p>
<p>&nbsp;</p>
<p>02/2019: France Tech Transfer Invest (FFTI) Tech Tour winner<br />
➞<a href="https://www.atlanpole.fr/actualites/goliver-therapeutics-laureat-biotech-de-la-france-tech-transfer-invest-2019/">https://www.atlanpole.fr/actualites/goliver-therapeutics-laureat-biotech-de-la-france-tech-transfer-invest-2019/</a></p>
<p>&nbsp;</p>
<p>12/2018: European Union (ERDF) funding of €400,000 to develop the first stages of bioproduction process industrialization (2018-2020).</p>
<p>&nbsp;</p>
<p>08/2018: GoLiver Therapeutics Receives a Positive Scientific Advice from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on its Biomanufacturing Strategy for Acute Liver Failure</p>
<p>&nbsp;</p>
<p>05/2018: Published paper. Garnier D, et al. Nguyen TH. Expansion of human primary hepatocytes in vitro through their amplification as liver progenitors in a 3D organoid system. Sci Rep. 2018 May 29;8(1):8222.<br />
➞<a href="https://pubmed.ncbi.nlm.nih.gov/29844473/">https://pubmed.ncbi.nlm.nih.gov/29844473/</a></p>
<p>&nbsp;</p>
<p>01/2018: Forum Atlanpole award (<a href="https://www.lejournaldesentreprises.com/loire-atlantique-vendee/breve/goliver-therapeutics-la-start-coup-de-coeur-du-forum-atlanpole-114098">https://www.lejournaldesentreprises.com/loire-atlantique-vendee/breve/goliver-therapeutics-la-start-coup-de-coeur-du-forum-atlanpole-114098</a>) <a href="https://www.youtube.com/watch?v=gAXCBni7OuQ&amp;t=11s">View video</a><br />
➞ FORUM ATLANPOLE : EFFERVESCENCE, ENERGIE, AMBITION , rédigé par Atlanpole -&gt; <a href="https://www.atlanpole.fr/actualites/forum-atlanpole-effervescence-energie-ambition/">View link</a><br />
➞ Biothérapie : une start-up issue d’un laboratoire de l’Université de Nantes primée, rédigé par SFR Bonamy -&gt;<a href="http://www.sfrsante.univ-nantes.fr/accueil/la-recherche-en-sante-pour-tous/biotherapie-une-start-up-issue-d-un-laboratoire-de-l-universite-de-nantes-primee-2177179.kjsp">View link</a><br />
➞ Goliver Therapeutics, la start-up coup de coeur du forum Atlanpole, rédigé par Le journal des Entreprises -&gt; <a href="https://www.lejournaldesentreprises.com/loire-atlantique-vendee/breve/goliver-therapeutics-la-start-coup-de-coeur-du-forum-atlanpole-114098">View link</a><br />
➞ Biothérapie. Goliver s’attaque à la régénérescence du foie sans greffe à Nantes, rédigé par Ouest France -&gt; <a href="https://www.ouest-france.fr/economie/entreprises/biotherapie-goliver-s-attaque-la-regenerence-du-foie-sans-transplantation-5503252">View link</a><br />
➞ Innovation. Chez Atlanpole, les start-up suivies ont un taux de survie de 89 %, rédigé par Ouest France -&gt; <a href="https://www.ouest-france.fr/economie/entreprises/innovation-chez-atlanpole-les-start-suivies-ont-un-taux-de-survie-de-89-5503262">View link</a><br />
➞ 5 entreprises innovantes à suivre en 2018, rédigé par Nantes Métropole -&gt; <a href="https://www.nantesmetropole.fr/actualite/l-actualite-thematique/5-entreprises-innovantes-a-suivre-en-2018-enseignement-et-recherche-97040.kjsp">View link</a></p>
<p>&nbsp;</p>
<p>01/2018: Published paper. Kilens S, et al. Parallel derivation of isogenic human primed and naive induced pluripotent stem cells. Nat Commun. 2018 Jan 24;9(1):360.<br />
➞<a href="https://pubmed.ncbi.nlm.nih.gov/29367672/">https://pubmed.ncbi.nlm.nih.gov/29367672/</a></p>
<p>&nbsp;</p>
<p>04/2017: Creation of GoLiver Therapeutics – Greffe du Tribunal de Commerce de NANTES<br />
-&gt; <a href="https://www.infogreffe.fr/entreprise-societe/829253806-goliver-therapeutics-440117B012670000.html?typeProduitOnglet=EXTRAIT&amp;afficherretour=false">View link</a></p>
<p>&nbsp;</p>
<p>07/2016: Grand Prize -I-Lab start-up innovation contest award<br />
➞ i-LAB 2016 -Les 5 Grands prix : Tuan Huy Nguyen – GOLIVER, rédigé par Minisère Enseignement supérieur, Recherche et Innovation -&gt; <a href="http://www.dailymotion.com/video/x4kbuh4">View link</a><br />
➞ 56 lauréats et 5 grands prix pour le concours i-LAB 2016 | Bpifrance, rédigé par BPI France -&gt; <a href="http://www.bpifrance.fr/A-la-une/Actualites/56-laureats-et-5-grands-prix-pour-le-concours-i-LAB-2016-27368">View link</a><br />
➞ C’est le premier grand prix du concours i-Lab décerné à une start-up de la région Pays de la Loire, rédigé par Atlanpole -&gt; <a href="https://www.atlanpole.fr/actualites/goliver-grand-prix-concours-i-lab-2016/">View link</a><br />
➞ Goliver, Grand prix du concours i-Lab 2016, rédigé par Atlanpole -&gt; <a href="http://www.atlanpolebiotherapies.com/actualites/goliver/">View link</a><br />
➞ Concours i-LAB Parmi les 5 grands prix du Concours i-LAB, 4 ont été maturés dans une SATT -&gt; <a href="http://www.satt.fr/i-lab-2016/">View link</a><br />
➞ Palmarès du concours I-LAB 2016, rédigé par Biotech.info -&gt; <a href="http://www.biotechinfo.fr/palmares-des-laureats-du-concours-i-lab-2016/">View link</a><br />
➞ GoLiver, primé d’un Grand Prix au concours i-LAB 2016, propose des solutions thérapeutiques innovantes pour le traitement des maladies du foie -&gt; <a href="https://www.curie.asso.fr/i-LAB-2-3-Universite-de-Nantes-Inserm-Ouest-Valorisation.html">View link</a><br />
➞ 56 lauréats et 5 grands prix pour le concours i-LAB 2016 – 12/07/2016, rédigé par La dépêche -&gt; <a href="https://www.ladepeche.fr/article/2016/07/12/2555170-56-laureats-5-grands-prix-concours-i-lab-2016-2016.html">View link</a></p>
<p>&nbsp;</p>
<p>04/2016: Start West award<br />
➞ <a href="https://www.start-west.com/a-propos/bilan-2016/">https://www.start-west.com/a-propos/bilan-2016/</a><br />
➞ Le 18h Eco : Goliver ou la naissance d’une start-up sur Orange Vidéos, rédigé par Télénantes -&gt; <a href="https://www.youtube.com/watch?v=aoWjYjrbumE">View link</a><br />
➞ Cinq start-up qui vont plaire aux investisseurs, rédigé par Capital -&gt; <a href="https://www.capital.fr/entreprises-marches/cinq-start-up-qui-vont-plaire-aux-investisseurs-1113971">View link</a><br />
➞ Innovation – 5 pépites distinguées à Start West – Agence API, rédigé par API -Region Bretagne – Pays de la Loire -&gt; <a href="https://www.agence-api.fr/article/innovation-a-5-pacpites-distinguaces-a-start-west">View link</a><br />
➞ GoLiver, lauréat du concours Start West, rédigé par Progreffe -&gt; <a href="http://www.progreffe.com/wp-content/uploads/sites/3/2016/07/lettre-progreffe-n14.pdf">View link</a><br />
➞ Région_Bretagne – Les lauréats bretons de Start West 2016, rédigé par Region Bretagne -&gt; <a href="http://www.bretagne.bzh/jcms/prod_325215/fr/les-laureats-bretons-de-start-west-2016">View link</a></p>
<p>&nbsp;</p>
<p>12/2015: Published paper. Tolosa L, Caron J, Hannoun Z, Antoni M, López S, Burks D, Castell JV, Weber A, Gomez-Lechon MJ, Dubart-Kupperschmitt A. Transplantation of hESC-derived hepatocytes protects mice from liver injury. Stem Cell Res Ther. 2015 Dec 12;6:246.<br />
➞ <a href="https://pubmed.ncbi.nlm.nih.gov/26652177/">https://pubmed.ncbi.nlm.nih.gov/26652177/</a></p>
<p>&nbsp;</p>
<p>07/2015: I-Lab « émergence » start-up innovation contest award -&gt; <a href="http://www.enseignementsup-recherche.gouv.fr/cid90838/i-lab-2015-remise-des-prix-le-1er-juillet-2015.html">View link</a></p>
<p>&nbsp;</p>
<p>12/2011 : FP7-EU Innovaliv project – Innovative strategies to generate human hepatocytes for treatment of metabolic Liver diseases: Tools for personalized cell therapy, rédigé par Europe<br />
-&gt; <a href="https://cordis.europa.eu/project/rcn/102127_en.html">View link</a></p>
<p>&nbsp;</p>
<p>02/2009 : FP7 -EU LIV-ES project – Lancement de LIV-ES, un projet de recherche européen visant à développer des thérapies innovantes pour les maladies associées au foie, rédigé par Europe<br />
-&gt; <a href="https://cordis.europa.eu/news/rcn/118869_es.html">View link</a></p>
<div id="gtx-trans" style="position: absolute; left: 6px; top: 70.6667px;">
<div class="gtx-trans-icon"></div>
</div>The post <a href="https://golivertx.com/news-about-golivertx/?lang=en">News about GoliverTX</a> first appeared on <a href="https://golivertx.com/?lang=en">Golivertx</a>.]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
